Abstract：The aim of the present study was to explore the value of baseline serum exosomal miR-155-5p expression level combined with HBV DNA quantification in predicting HBeAg seroconversion in chronic hepatitis B (CHB) patients treated with peginterferon (Peg-IFN) for 48 weeks. A total of 88 HBeAg-positive CHB patients who initially received Peg-IFN therapy in our hospital from June 2016 to June 2019 were retrospectively analyzed. Patients were divided into treatment response and non-response group according to HBeAg seroconversion after Peg-IFN treatment for 48 weeks. Multivariate logistic regression analysis was performed to identify predictors of treatment response, and the area under receiver operating characteristic (ROC) curve was used to evaluate the predictive efficacy. The results indicated that baseline serum exosomal miR-155-5p [odds ratio (OR) ＝2.193, 95% confidence interval (CI) 1.315～3.655, P＝0.003] and HBV DNA (OR＝0.398, 95% CI 0.163～0.976, P＝0.036) were independent predictors for HBeAg seroconversion. The optimal cut-off value of baseline serum exosomal miR-155-5p and HBV DNA were 2.3 and 7.2 log10IU/mL, respectively; and the corresponding area under ROC curves were 0.788 (95% CI 0.682～0.893) and 0.704 (95% CI 0.577～0.824), respectively. Patients with baseline serum exosomal miR-155-5p expression level ≥2.3 and HBV DNA ≤7.2 log10IU/mL had 66.67% (10/15) rates of HBeAg seroconversion, whereas the rates of HBeAg seroconversion among patients with unfavorable baseline characteristics were only 3.03% (1/33). Taken together, these results suggest that baseline serum exosomal miR-155-5p combined with HBV DNA quantification may serve as a useful predictor of Peg-IFN therapy efficacy in HBeAg-positive CHB patients.
胡乾坤，王倩倩，李强，黄晨璐，许伟，张毅，李新艳，陈良，黄玉仙. 基线血清外泌体miR-155-5p联合乙型肝炎病毒DNA定量实验预测聚乙二醇干扰素治疗乙型肝炎e抗原阳性慢性乙型肝炎的疗效[J]. 微生物与感染, 2020, 15(6): 385-392.
HU Qiankun, WANG Qianqian, LI Qiang, HUANG Chenlu, XU Wei, ZHANG Yi, LI Xinyan, CHEN Liang, HUANG Yuxian. Baseline serum exosomal miR-155-5p combined with HBV DNA can predict HBeAg seroconversion in chronic hepatitis B patients receiving peginterferon. JOURNAL OF MICROBES AND INFECTIONS, 2020, 15(6): 385-392.
Schweitzer A, Horn J, Mikolajczyk R T, Krause G, Ott J J. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013[J]. Lancet,2015,386(10003):1546-1555.
[2]
Lau G K, Piratvisuth T, Luo K X, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried M W, Chow W C, Paik S W, Chang W Y, Berg T, Flisiak R, Mccloud P, Pluck N. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B[J]. N Engl J Med,2005,352(26):2682-2695.
[3]
Buster E H, Hansen B E, Lau G K, Piratvisuth T, Zeuzem S, Steyerberg E W, Janssen H L. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa[J]. Gastroenterology,2009,137(6):2002-2009.
[4]
Piratvisuth T, Marcellin P, Popescu M, Kapprell H P, Rothe V, Lu Z M. Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients[J]. Hepatol Int,2013,7(2):429-436.
[5]
Beermann J, Piccoli M T, Viereck J, Thum T. Non-coding RNAs in Development and Disease: Background, Mechanisms, and Therapeutic Approaches[J]. Physiol Rev,2016,96(4):1297-1325.
[6]
Ge J, Huang Z, Liu H, Chen J, Xie Z, Chen Z, Peng J, Sun J, Hou J, Zhang X. Lower Expression of MicroRNA-155 Contributes to Dysfunction of Natural Killer Cells in Patients with Chronic Hepatitis B[J]. Front Immunol,2017,8:1173.
[7]
Fang J, Zhuge L, Rao H, Huang S, Jin L, Li J. Increased Levels of miR-155 are Related to Higher T-Cell Activation in the Peripheral Blood of Patients with Chronic Hepatitis B[J]. Genet Test Mol Biomarkers,2019,23(2):118-123.
[8]
Su C, Hou Z, Zhang C, Tian Z, Zhang J. Ectopic expression of microRNA-155 enhances innate antiviral immunity against HBV infection in human hepatoma cells[J]. Virol J,2011,8:354.
[9]
Lugli G, Cohen A M, Bennett D A, Shah R C, Fields C J, Hernandez A G, Smalheiser N R. Plasma Exosomal miRNAs in Persons with and without Alzheimer Disease: Altered Expression and Prospects for Biomarkers[J]. Plos One,2015,10(10):e139233.
[10]
Min L, Zhu S, Chen L, Liu X, Wei R, Zhao L, Yang Y, Zhang Z, Kong G, Li P, Zhang S. Evaluation of circulating small extracellular vesicles derived miRNAs as biomarkers of early colon cancer: a comparison with plasma total miRNAs[J]. J Extracell Vesicles,2019,8(1):1643670.
Enderle D, Spiel A, Coticchia C M, Berghoff E, Mueller R, Schlumpberger M, Sprenger-Haussels M, Shaffer J M, Lader E, Skog J, Noerholm M. Characterization of RNA from Exosomes and Other Extracellular Vesicles Isolated by a Novel Spin Column-Based Method[J]. Plos One,2015,10(8):e136133.
Schmittgen T D, Livak K J. Analyzing real-time PCR data by the comparative C(T) method[J]. Nat Protoc,2008,3(6):1101-1108.
[15]
Pan X B, Ma H, Jin Q, Wei L. Characterization of microRNA expression profiles associated with hepatitis B virus replication and clearance in vivo and in vitro[J]. J Gastroenterol Hepatol,2012,27(4):805-812.
[16]
Li J, Zhang X, Chen L, Zhang Z, Zhang J, Wang W, Wu M, Shi B, Zhang X, Kozlowski M, Hu Y, Yuan Z. Circulating miR-210 and miR-22 combined with ALT predict the virological response to interferon-alpha therapy of CHB patients[J]. Sci Rep,2017,7(1):15658.
[17]
Seddiki N, Brezar V, Ruffin N, Lévy Y, Swaminathan S. Role of miR-155 in the regulation of lymphocyte immune function and disease[J]. Immunology,2014,142(1):32-38.
[18]
Wang P, Hou J, Lin L, Wang C, Liu X, Li D, Ma F, Wang Z, Cao X. Inducible microRNA-155 feedback promotes type I IFN signaling in antiviral innate immunity by targeting suppressor of cytokine signaling 1[J]. J Immunol,2010,185(10):6226-6233.
[19]
Sarkar N, Panigrahi R, Pal A, Biswas A, Singh S P, Kar S K, Bandopadhyay M, Das D, Saha D, Kanda T, Sugiyama M, Chakrabarti S, Banerjee A, Chakravarty R. Expression of microRNA-155 correlates positively with the expression of Toll-like receptor 7 and modulates hepatitis B virus via C/EBP-β in hepatocytes[J]. J Viral Hepat,2015,22(10):817-827.
[20]
El A S, M?ger I, Breakefield X O, Wood M J. Extracellular vesicles: biology and emerging therapeutic opportunities[J]. Nat Rev Drug Discov,2013,12(5):347-357.
[21]
Huang X, Yuan T, Tschannen M, Sun Z, Jacob H, Du M, Liang M, Dittmar R L, Liu Y, Liang M, Kohli M, Thibodeau S N, Boardman L, Wang L. Characterization of human plasma-derived exosomal RNAs by deep sequencing[J]. Bmc Genomics,2013,14:319.
[22]
Bala S, Petrasek J, Mundkur S, Catalano D, Levin I, Ward J, Alao H, Kodys K, Szabo G. Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases[J]. Hepatology,2012,56(5):1946-1957.
[23]
Matsuura K, De Giorgi V, Schechterly C, Wang R Y, Farci P, Tanaka Y, Alter H J. Circulating let-7 levels in plasma and extracellular vesicles correlate with hepatic fibrosis progression in chronic hepatitis C[J]. Hepatology,2016,64(3):732-745.
[24]
Boukouris S, Mathivanan S. Exosomes in bodily fluids are a highly stable resource of disease biomarkers[J]. Proteomics Clin Appl,2015,9(3-4):358-367.
[25]
Goldie B J, Dun M D, Lin M, Smith N D, Verrills N M, Dayas C V, Cairns M J. Activity-associated miRNA are packaged in Map1b-enriched exosomes released from depolarized neurons[J]. Nucleic Acids Res,2014,42(14):9195-9208.
[26]
Fan R, Sun J, Yuan Q, Xie Q, Bai X, Ning Q, Cheng J, Yu Y, Niu J, Shi G, Wang H, Tan D, Wan M, Chen S, Xu M, Chen X, Tang H, Sheng J, Lu F, Jia J, Zhuang H, Xia N, Hou J. Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues[J]. Gut,2016,65(2):313-320.
2020, Vol. 15 
